🇺🇸 FDA
Patent

US 12268700

3-o-sulfo-galactosylceramide analogs as activators of type II NKT cells and uses thereof

granted A61KA61K31/7032A61K38/1774

Quick answer

US patent 12268700 (3-o-sulfo-galactosylceramide analogs as activators of type II NKT cells and uses thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/7032, A61K38/1774, A61K38/193, A61K39/3955